Scientific Programme

Thursday, 10 October 2019

10.00  Registration opens

12.00 – 14.00  ESU Course: New challenges and unmet needs in basic science and histopathology to address the clinical management of renal malignancies
Chair  M. Hora, Plzen (CZ)
Faculty  A. Hartmann, Erlangen (DE); R. Leao, Coimbra (PT)

See ESUR19 website for full ESU Course programme

14.30 – 14.45  Opening
Carmen Jeronimo, Porto (PT)  Meeting Chair
Kerstin Junker, Homburg (DE)  ESUR Chair
Rodolfo Montironi, Ancona (IT) ESUP Chair

14.45 – 16.10  Session 1
Microenvironment, metabolism and epigenetic reprogramming

14.45 – 15.10  Phenotype-independent DNA methylation changes in prostate cancer
Norman Maitland, York (GB)

15.10 – 15.30  The tumour-microenvironment as a barrier or enabler of the host immune response
Gabriel Malouf, Strasbourg, France

15.30 – 15.50  MicroRNA expression and activity in the prostate cancer tumour microenvironment
Shawn Lupold, Baltimore US

15.50 – 16.10  The multifunctional role of the enzyme APE1/Ref-1 in bladder cancer: Growth, cell survival and muscle invasion
Travis Jerde, Indianapolis (US)

16.10 – 16.40  Break

16.40 – 17.40  Session 2
Translational research in bladder dysfunction

16.40 – 17.00  RNA profiling in bladder pathologies
Katia Monastyrskaya, Berne (CH)

17.00 – 17.20  Neurotrophins and stress in bladder pain
Ana Charrua, Porto (PT)

17.20 – 17.40  Regulating axonal growth for spinal cord regeneration
Martin Schwab, Zurich (CH)

17.40 – 18.30  Short presentations 1
Friday, 11 October 2019

08.30 – 09.20  Session 3
Epidrugs: From basics to clinical trials

08.30 – 08.55  Clinical trials on epigenetic therapies for urological tumours
Simon Crabb, Southampton (GB)

08.55 – 09.20 Epidrugs designing
Paola Arimondo, Paris (FR)

09.20 – 10.20  Session 4
Immuno-oncology: pre клинические и клинические испытания: Pre-clinical studies

09.20 – 09.40 Inhibition of a G9a/EZH2 network triggers an immune-mediated bladder cancer regression
Jesus Paramio, Madrid (ES)

09.40 – 10.00 Oncolytic viruses as a kick-start for immunotherapy
Gabri van der Pluijm, Leiden (NL)

10.00 – 10.20 Mechanisms of action and resistance to BCG immunotherapy: New developments
Joost Boormans, Rotterdam (NL)

10.20 – 10.50 Break

10.50 – 11.50 Session 5
Immuno-oncology: pre-clinical and clinical trials: Clinical trials

10.50 – 11.10 Immunotherapy combinations and sequences in urothelial cancer: Facts and hopes
Yohann Loriot, Villejuif (FR)

11.10 – 11.30 New combination partners of IO (eg. anti-angiogenesis) in RCC (preclinical concept and recent clinical studies)
Andreas Pircher, Innsbruck (AT)

11.30 – 11.50 Novel approaches to targeting the androgen receptor in CRPC
Ganesh Raj, Dallas (US)

11.50 – 12.30 Short presentations 2

12.30 – 13.30 Lunch

13.30 – 15.00 Poster session 1

14.45 – 15.00 Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00 – 16.50</td>
<td>Session 6</td>
<td>Panel session: Local therapy in metastatic prostate cancer</td>
<td></td>
</tr>
<tr>
<td>15.00 – 15.20</td>
<td>Salvage lymph node dissection for nodal recurrent prostate cancer</td>
<td>Guillaume Ploussard, Toulouse (FR)</td>
<td></td>
</tr>
<tr>
<td>15.20 – 16.05</td>
<td>Therapy of oligometastatic prostate cancer in 2019</td>
<td>Noel Clarke, Manchester (GB)</td>
<td></td>
</tr>
<tr>
<td>15.20 – 15.35</td>
<td>Radiotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.35 – 15.50</td>
<td>Surgery</td>
<td>Matthias Saar, Homburg (DE)</td>
<td></td>
</tr>
<tr>
<td>15.50 – 16.05</td>
<td>Hormonal therapy</td>
<td>Igor Tsaur, Mainz (DE)</td>
<td></td>
</tr>
<tr>
<td>16.05 – 16.25</td>
<td>Role of primary tumour for metastasis development and therapy response (including exosomes)</td>
<td>Bruno Costa-Silva, Lisbon (PT)</td>
<td></td>
</tr>
<tr>
<td>16.25 – 16.50</td>
<td>Panel discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.50 – 17.30</td>
<td>Short presentations 3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Saturday, 12 October 2019

08.45 – 09.50  Session 7
Molecular subtypes and therapeutics

08.45 – 09.10  Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal
Scott Shepherd, London (GB)

09.10 – 09.30  Histopathological subtypes in RCC: consequences for systemic therapy
Holger Moch, Zurich (CH)

09.30 – 09.50  Sequencing of prostate cancers identifies new cancer genes, routes of progression and
drug targets
David Wedge, Oxford (GB)

09.50 – 10.30  Short presentations 4

10.30 – 11.00  Break

11.00 – 11.30  Session 8: Data protection regulation and ethics

11.00 – 11.30  Open consent, biobanking and data protection law: Can open consent be ‘informed’
under the forthcoming data protection regulation?
Dara Hallinan, Karlsruhe (DE)

11.30 – 12.30  Short presentations 5

12.30 – 13.30  Lunch

13.30 – 15.00  Poster session 2

14.45 – 15.00  Break

15.00 – 15.30  Dominique Chopin Award and lecture

15.30 – 16.00  ARTP Award and closing remarks